Authors: Micallef, J Soubrouillard, C Guet, F Le Guern, ME Alquier, C Bruguerolle, B Blin, O

Citation: J. Micallef et al., A double blind parallel group placebo controlled comparison of sedative and amnesic effects of etifoxine and lorazepam in healthy subjects, FUN CL PHAR, 15(3), 2001, pp. 209-216

Authors: Rascol, O Nutt, JG Blin, O Goetz, CG Trugman, JM Soubrouillard, C Carter, JH Currie, LJ Fabre, N Thalamas, C Giardina, WJ Wright, S

Citation: O. Rascol et al., Induction by dopamine D-1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease, ARCH NEUROL, 58(2), 2001, pp. 249-254

Authors: Masson, GS Mestre, DR Martineau, F Soubrouillard, C Brefel, C Rascol, O Blin, O

Citation: Gs. Masson et al., Lorazepam-induced modifications of saccadic and smooth-pursuit eye movements in humans: attentional and motor factors, BEH BRA RES, 108(2), 2000, pp. 169-180

Authors: Dingemanse, J Soubrouillard, C Paris, J Pisano, P Blin, O

Citation: J. Dingemanse et al., Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorptionof IS-159, a peptide serotonin 1B/1D-receptor agonist, CLIN PHARM, 68(2), 2000, pp. 114-121

Authors: Rascol, O Blin, O Thalamas, C Descombes, S Soubrouillard, C Azulay, P Fabre, N Viallet, F Lafnitzegger, K Wright, S Carter, JH Nutt, JG

Citation: O. Rascol et al., ABT-431, a D1 receptor agonist prodrug, has efficacy in Parkinson's disease, ANN NEUROL, 45(6), 1999, pp. 736-741